Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.

Seminars in oncology - 1 Dec 1995

Rosell R, González-Larriba J L, Alberola V, Molina F, Monzó M, Benito D, Pérez J M, de Anta J M

Abstract excerpt

Currently available cytotoxic drugs are only moderately active in non-small cell lung cancer (NSCLC) and prolong survival only slightly. In two published trials, single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was reported to have significant activity in NSCLC, with r...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Genes, p53

Share to Genes, ras

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 8553077

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-8553077-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.PMID 8553077Read ↗

p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma.Semantic proximity Read ↗

Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.Semantic proximity Read ↗

Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor.Semantic proximity Read ↗

p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma.Semantic proximity Read ↗

Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice.Semantic proximity Read ↗

Molecular effects of paclitaxel: Myths and reality (a critical review)Semantic proximity Read ↗

p53-independent apoptosis induced by paclitaxel through an indirect mechanismSemantic proximity Read ↗

Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of Paclitaxel.Semantic proximity Read ↗

<i>MRP7/ABCC10</i>expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancerSemantic proximity Read ↗

Role of p53 in the induction of cyclooxygenase-2 by cisplatin or paclitaxel in non-small cell lung cancer cell lines.Semantic proximity Read ↗

Induction of senescence-like phenotype and loss of paclitaxel sensitivity after wild-type p53 gene transfection of p53-null human non-small cell lung cancer H358 cells.Semantic proximity Read ↗

Low dose fractionated radiation enhances the radiosensitization effect of paclitaxel in colorectal tumor cells with mutant p53.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.